At $4.3 B in annual revenue, Belgium-based UCB S.A. would place about 14th among Fortune 500 US pharmaceutical companies. But unlike its larger peers, whose industry-consolidating mergers have massive layoffs, all for the sake of cost-cutting earnings growth, UCB focused its business model innovations on unique advantage. As a result, UCB is delighting patients and employees alike.